300 million at full capacityI've kept the company on my watch list, and have been following the NRs, and it is my opinion, they have done great work at promoting their efforts, targeting the international markets, and informing retail and institutional investors why Supreme is becoming a second tier company within the industry.
I've also researched why the other completed rooms were not inspected when the NR came out in January. When a company has a number of rooms ready for inspection, a request is forwarded to Health Canada, and upon their attendance to the site, HC is restricted to the rooms listed on the request, therefore any rooms completed in the interim cannot be inspected on that perticular day. Another request needs to be filed.
Hopefully the company can maintain this traction, I believe the market is slowly reacting to this company. The company should be on schedule to have the rooms completed by the end of this month, but as mentioned above, the inspection process might take a few months to be completed.
Q3 should be respectable, but Q4 should be exceptional, giving this company superb momentum entering 2020.
As long as it's able to continue it's respectable climb, I'll consider getting back before Q3. Still heavely manipulated, but if the news releases, and progression come out in a timely fashion, the SP should be respectible for the fall, and once at full capacity, debentures etc won't really matter, if the SP reflects their progress.
I always agreed with the comments regarding fundementals, and quality product, I had issues with the release of information/marketing, but I believe they've stepped up their game.
Regarding the analyses, the target price reflects the recent financials, once Q3 and Q4 are out, the outlook will change drastically, and who knows might become a top tier company. Hopefully the company can get out of this penny stock stage between now and the fall, so the fundementals can really take over.
Good Luck to everyone